ClinicalTrials.gov
ClinicalTrials.gov Menu

Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00997633
Recruitment Status : Completed
First Posted : October 19, 2009
Last Update Posted : October 19, 2009
Sponsor:
Information provided by:
Uppsala University

Brief Summary:
SPECT was performed in 51 patients after cytoreductive surgery in combination with intraperitoneal chemotherapy. The detected volume was compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses that could be performed without further surgical intervention. SPECT data was found to predict feasibility of sequential postoperative intraperitoneal chemotherapy.

Condition or disease
Peritoneal Carcinomatosis

Study Type : Observational
Actual Enrollment : 51 participants
Observational Model: Case-Only
Official Title: Single-photon Emission Computed Tomography for Prediction of Treatment Results in Sequential Intraperitoneal Chemotherapy at Peritoneal Carcinomatosis
Study Start Date : May 1991
Actual Primary Completion Date : August 2004
Actual Study Completion Date : August 2004

Group/Cohort
Peritoneal carcinomatosis
Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment



Primary Outcome Measures :
  1. Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses

Secondary Outcome Measures :
  1. The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 74 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who had undergone cytoreductive surgery and intraperitoneal chemotherapy (SPIC) at the Dept of Surgical Sciences, Uppsala University Hospital in the time period between May 1991 and August 2004.
Criteria

Inclusion Criteria:

  • Cytoreductive surgery and intraperitoneal chemotherapy
  • Single-Photon Emission Computed Tomography (SPECT) before the second course of treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997633


Locations
Sweden
Dept of Surgical Sciences, Section of Surgery
S-751 85 Uppsala, Sweden
Sponsors and Collaborators
Uppsala University
Investigators
Principal Investigator: Haile Mahteme, MD PhD Dept of Surgical Sciences, University Hospital, Uppsala, Sweden

Responsible Party: Haile Mahteme, MD PhD, Dept of Surgical Sciences, Section of Surgery, Uppsala University, Sweden
ClinicalTrials.gov Identifier: NCT00997633     History of Changes
Other Study ID Numbers: SPECT IK1991:5
First Posted: October 19, 2009    Key Record Dates
Last Update Posted: October 19, 2009
Last Verified: October 2009

Keywords provided by Uppsala University:
Intraperitoneal volume
peritoneal carcinomatosis
cytoreductive surgery
SPECT
intraperitoneal chemotherapy

Additional relevant MeSH terms:
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms